

For Immediate Release
For Further Information Contact:
Andrew Fisher at (301) 608-9292
Email: Afisher@unither.com

**REMODULIN® LONG-TERM DATA PRESENTED AT
EUROPEAN RESPIRATORY SOCIETY CONFERENCE**

Silver Spring, MD, October 2, 2003: United Therapeutics Corporation (NASDAQ: UTHR) announced today that data on the use of rapid dosing strategies and the long term efficacy of Remodulin were presented at the European Respiratory Society meeting in Vienna, Austria.

Nika Skoro-Sajer, MD of the University of Vienna, Allgemeines Krankenhaus, Vienna, Austria, presented long-term data on 19 patients treated with Remodulin over approximately 16 months. Dr. Skoro-Sajer reported that patients experienced significant reductions in mean pulmonary arterial pressure and pulmonary vascular resistance. Cardiac index also improved significantly. Furthermore, the mean six-minute walk distance increased by 121 meters from baseline and the average NYHA classification improved from 3.2 to 2.4.

“These data, together with very similar findings presented by Dr. Gomez-Sanchez from Madrid during the last European Society of Cardiology meeting and that Dr. Vachiery from Brussels will be presenting at the upcoming American Heart Association meeting in Orlando, provide compelling evidence that Remodulin confers long-term benefits for patients with severe pulmonary arterial hypertension,” said Irene Lang, MD and Meinhard Kneussl, MD of the Vienna Allgemeines Krankenhaus.

Remodulin (treprostinil sodium) Injection is approved in the United States as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of pulmonary arterial hypertension.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncological diseases with unique therapeutic products.

* * *